Despite these intrinsic limitations, the use of core biomarkers in the AD diagnostic workup improves accuracy (up to 90%) with a relevant impact on AD stratification and selection for disease-modifying trials tailored against Aß and tau pathologies [29]. This evidence concerns the gene MAPT and Alzheimer disease.